Liu Ying-Ying, Chen Tao, Shen Dan, Zhang Wei-Yun, Wang Chang-Guo, Jiang Jun-Hong, Zeng Da-Xiong
Department of Respiratory and Critical Care, the First Affiliated Hospital of Soochow University.
J Int Med Res. 2020 Mar;48(3):300060519887276. doi: 10.1177/0300060519887276. Epub 2019 Dec 18.
The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand-foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy.
在过去几十年里，小细胞肺癌（SCLC）的治疗方案变化不大。阿帕替尼是一种血管内皮生长因子受体-2酪氨酸激酶的小分子抑制剂。阿帕替尼已显示出对晚期胃癌和乳腺癌有效，最近的研究也报道了其在非小细胞肺癌中的成功应用；然而，其在小细胞肺癌中的疗效仍不明确。在本研究中，我们使用阿帕替尼作为化疗难治性小细胞肺癌的挽救治疗。5例晚期小细胞肺癌男性患者接受口服阿帕替尼（250mg/天）作为二线至四线治疗。1例患者对阿帕替尼有部分缓解，1例病情稳定，3例患者病情进展。病情稳定和部分缓解患者的无进展生存期分别为1.5个月和3个月。只有3例患者出现不良反应，分别为轻度高血压、呕吐和手足综合征，所有这些不良反应均可控。因此，阿帕替尼可能是晚期小细胞肺癌患者化疗后的一种挽救选择。
